Press Releases

GI Dynamics, Inc. Reports on Progress of the ENDO Trial

LEXINGTON, Massachusetts & SYDNEY, Australia – 25 April 2013 – GI Dynamics, Inc. (ASX: GID) today announced an update on the status of the ENDO Trial, its U.S. multi-center, pivotal clinical trial of EndoBarrier® for the treatment of patients who have uncontrolled type 2 diabetes and are...

read more

EndoBarrier® Therapy Named Product of the Year by BioSpectrum Asia

LEXINGTON, Massachusetts & SYDNEY – 18 March 2013 – GI Dynamics, Inc. (ASX: GID) today announced that EndoBarrier® Therapy, the Company’s non-surgical, non-pharmaceutical treatment for type 2 diabetes and/or obesity, was selected by an independent panel of international life sciences experts...

read more

EndoBarrier® Therapy Named Product of the Year by BioSpectrum Asia

LEXINGTON, Massachusetts & SYDNEY – 18 March 2013 – GI Dynamics, Inc. (ASX: GID) today announced that EndoBarrier® Therapy, the Company’s non-surgical, non-pharmaceutical treatment for type 2 diabetes and/or obesity, was selected by an independent panel of international life sciences experts...

read more

GI Dynamics Announces Resolution of Litigation with Gore

Gore Drops All Claims Against GI Dynamics Lexington, Massachusetts, United States and Sydney, Australia – 9 January 2013 – GI Dynamics, Inc. (GI Dynamics or the Company) (ASX: GID) today announced that it has reached a settlement with W.L. Gore & Associates (Gore) in litigation brought by Gore...

read more
Page 12 of 18« First...1011121314...Last »